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Aim: To investigate serum HLA-G levels and its correlation with oxidative stress and antioxidant parameters in breast cancer patients.
Materials and methods: The patient group consisted of 25 individuals with breast cancer who were operated on in the General Surgery
Department of Gazi University’s Faculty of Medicine. Thirty-one individuals who had no history of any kind of cancer, allergic diseases,
diabetes, or rheumatic and immunological disease constituted the control group.
Results: Results showed that malondialdehyde (MDA), advanced oxidation protein products (AOPPs), and HLA-G levels in the patient
group were statistically and significantly high compared to the control group (P < 0.001). While vitamin C levels were significantly lower
in the patient group (P < 0.05), an insignificant difference in glutathione peroxidase (GPx) and total sulfhydryl group (R-SH) levels in
both groups was observed (P > 0.05). Serum superoxide dismutase (SOD) levels in the patient group were significantly low compared
to the control group (P < 0.001). In the control group, statistically significant positive correlations among HLA-G, MDA (r = 0.580, P =
0.001), and AOPP (r = 0.569, P = 0.01) were observed. In the control group, a significant positive correlation in MDA and AOPP levels
(r = 0.482, P = 0.006) was observed.
Conclusion: Results of the present study indicated that there was a relationship between the oxidative stress and the deficiency of
antioxidant defenses as lipid peroxidation, protein oxidation, and HLA-G expression increased.
Key words: Oxidative stress, antioxidants, breast cancer, HLA-G

1. Introduction
Breast cancer is the most frequently seen type of cancer
in the world. According to the results of a 2006 European
study, it ranked first among women, with a morbidity
rate of 28.9%. Breast cancer was responsible for 17.6% of
cancer-related deaths (1,2). It ranks first in cancer-related
deaths in every developed country except for Japan (3).
The molecular mechanisms underlying the development
of cancer have not been fully clarified yet. It is thought
that genetic damage (mostly cumulative in nature) leads
to the activation of protooncogenes and to deactivation of
tumor-suppressor genes, which triggers breast cancer. This
manifests as uncontrolled cell proliferation or the death of
the wrong cells and apoptosis (4). However, the fact that
the families of some individuals also have a cancer story
specific to the area or regions where they live indicates that
cancer can also be developed through genetic mutations (5).
Besides this, reactive oxygen species are thought to play a
* Correspondence: nedretk@gazi.edu.tr
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role in cancer development. Most of the risk factors for breast
cancer are related to overexposure to increased estrogen. It
is believed that estrogen stimulates the proliferation of the
breast cells, thereby increasing the chance of proliferation of
the cells that carry the mutated genes that may cause cancer
(4). Direct DNA damage can be incurred in the target tissue
without reacting with some estradiol estrone metabolites (6).
Cancer cells are characterized by a reduction in the control
of growth or no control at all, an invasion of the local tissues,
and metastasis (7).
Oxidative stress plays a role in the etiopathogenesis of
many benign or malign diseases, such as diabetes mellitus,
cardiovascular diseases, and cancer (8,9). Oxidative stress
is a natural process in all living forms that need oxygen,
and it is made up of several steps. Biological systems
incorporate some specific mechanisms that control this
stress. A lack of control mechanisms causes oxidative
damage (10,11).
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An increase in oxidative stress disturbs the balance
between the oxidant and antioxidant system. It also
causes molecular oxygen to produce some reactive
oxygen metabolites, such as superoxide radicals, hydrogen
peroxide, hydroxide, and peroxide radicals. The free
radical and reactive oxygen metabolites that are formed
lead to oxidative damage in DNA and lipids, which are the
fundamental structural molecules of the body (12–17).
Insufficient and suppressed response of the immune
system allows tumors to develop. The subgroups of HLA
molecules, whose relationship with several diseases has
been shown, are defined in the immune response (18,19).
HLA-G is not a typical class I molecule and the recent
research has shown that this molecule is likely to play a
role in the development of immunological tolerance. In
the research that has been carried out, HLA-G has been
detected in the peripheral blood and acidic liquids around
the tumor and in the tissues of cancer patients. It is known
that the HLA-G molecule is expressed by a number
of tumor tissues and that with the effect of the tumor
microsurrounding, the tumor escapes from the immune
system’s response. HLA-G molecules suppress natural
killer cells and T lymphocytes and allow an increase in the
secretion of cytokines (20–24).
The purpose of this study was to investigate whether
there is a relation between the levels of HLA-G and reactive
oxygen products caused by oxidative stress in the patient
group with breast cancer and in the healthy control group.
2. Materials and methods
2.1. Subjects
In this study, the patient group consisted of 25 patients
that had been operated on for breast cancer in the
Department of General Surgery in the Faculty of Medicine
at Gazi University. The control group consisted of 31
healthy individuals aged between 35 and 40 who did not
have any history of cancer, allergic diseases, diabetes,
or rheumatologic or immunologic diseases. HLA-G
analysis was carried out in the plasma samples taken from
patients and those in the control group, while the levels
of glutathione peroxidase (GPx), superoxide dismutase
(SOD), malonyldialdehyde (MDA), advanced oxidation
protein products (AOPPs), vitamin C, and total sulfhydryl
groups (R-SH) were measured in serums.
Blood samples were drawn from the patients and the
controls after overnight fasting, then centrifuged as soon
as possible at 2000 × g for 10 min at 4 °C. Serum and
plasma samples were stored at –70 °C until the analyses
were carried out.
AOPP levels were measured by a spectrophotometric
method in the presence of potassium iodide at 340 nm and
calibrated with chloramine-T solutions (25). AOPP levels
were expressed in micromoles chloramine-T equivalents

per liter. Lipid peroxidation (in terms of MDA) was
estimated using the thiobarbituric acid reactive substances
(TBARS) test as described previously (26). Briefly, TBARS
formation was quantified using 1,1,3,3-tetraethoxypropane
as the standard, and the absorbances of the TBARS
were read at 532 nm using a Shimadzu UV 1601
spectrophotometer (Shimadzu, Tokyo, Japan).
Reduced glutathione (GSH) levels were expressed as
total sulfhydryl group (R-SH) levels (27). First, 0.5 mL of
each sample was mixed with 1 mL of a solution containing
100 mM Tris-HCl (pH 8.2), 1% sodium dodecyl sulfate,
and 2 mM ethylene diamino tetra acetic acid. The mixture
was incubated for 5 min at 25 °C and centrifuged to
remove any precipitate. After that, 0.3 mM 5,5-dithiobis(2-nitrobenzoic acid) was then added to each reaction
volume and incubated for 15 min at 37 °C. The absorbance
of each sample was determined at 412 nm. The R-SH levels
were calculated assuming a molar extinction coefficient
of 13.000 mol–1 cm–1 at 412 nm. The SOD activity
measurements were carried out by inhibiting the SOD
activity via nitroblue tetrazolium reduction. Xanthine–
xanthine oxidase was used as a superoxide generator, and 1
IU was defined as the quantity of SOD required to produce
50% inhibition (28).
The
GPx
activity
was
determined
spectrophotometrically as described in the literature (29).
The reaction mixture, containing 50 mM phosphate buffer
(pH 7.4), 7.7 units GSH reductase, 5 mM GSH, and crude
extract, was preincubated for 5 min at 37 °C. Thereafter,
20 µL of nicotinamide adenine dinucleotide phosphate in
reduced form (NADPH) (0.3 mM) solution was added and
the hydroperoxide-independent consumption of NADPH
was monitored for about 5 min. The overall reaction was
started by adding 20 µL of prewarmed hydroperoxide
solution (0.025 mM). A decrease in absorption at 340 nm
was monitored.
The total level of ascorbate was determined by the
modified Roe and Kuether method (30). Serum samples
were added to trichloroacetic acid solution and centrifuged
at 3.000 × g for 10 min. 2,4-Dinitrophenylhydrazinethiourea-copper sulfate reagent was added to the serum
sample tubes. The contents of each tube were mixed,
capped with Parafilm, and placed in a water bath at 37 °C
for 4 h. The tubes were removed and cooled in ice water.
Ice-cold 65% sulfuric acid solution was added and mixed
thoroughly. The mixture was allowed to stand at room
temperature for 30 min, and absorbance was measured
using a Shimadzu UV 1601 spectrophotometer at 515
and 520 nm, respectively. The lower limit of detection for
vitamin C was 0.05 µmol/L. The determination of HLA-G
was done through enzyme-linked immunosorbent
assay (ELISA), one of the serological tests in researching
antibodies or antigens, using Bio Vonder Human sHLA-G
ELISA RD-1504.
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2.2. Statistical analysis
SPSS 15.0 for Windows was used for statistical analysis.
In detecting HLA-G, ROC analysis was used to find the
threshold level to diagnose the disease. The Student t-test
was used to find the differences in averages regarding the
variables examined in the control and the patient group.
The degree of the relationship between variables was
calculated through Pearson correlation analysis. P < 0.05
was taken as significant.
3. Results
In this study, we measured AOPP, MDA, SOD, GPx,
R-SH, vitamin C, and HLA-G levels in the samples drawn
from patients with breast cancer at phases 2 and 3, and
we examined the possible correlations among them. The
mean values of the investigated parameters are given in the
Table.

It has been observed that MDA, AOPP, and HLA-G
levels are significantly higher in patients with breast cancer
than those in the healthy control group (P < 0.001; Figures
1, 2, and 3, respectively).
The levels of vitamin C in patients with cancer are
significantly lower than in the control group (P < 0.05;
Figure 4), while there are no notable statistical differences
in GPx and R-SH levels (P > 0.05; Figure 5 and Figure 6,
respectively). Serum SOD levels have been found to be
significantly lower in patients with breast cancer than in
the control group (P < 0.001; Figure 7).
When the correlations of the parameters in both the
patient and control groups were examined, no notable
statistical correlations in the patient group were observed.
However, in the control group, statistically significant
positive correlations among HLA-G, MDA (r = 0.580, P
= 0.001), and AOPP (r = 0.569, P = 0.01) were observed.

Patient group
(n = 25)

Control group
(n = 31)

P

AOPP (µmol/L)

228.65 ± 127.00

138.31 ± 63.64

P < 0.001

MDA (nmol/mL)

11.42 ± 2.22

5.20 ± 1.63

P < 0.001

GPx (U/mL)

35.32 ± 32.79

32.14 ± 16.95

P > 0.05

Vitamin C (µmol/L)

1.66 ± 0.83

2.31 ± 1.09

P < 0.05

R-SH (nmol/mL)

278.47 ± 122.80

253.22 ± 43.93

P > 0.05

SOD (U/mL)

5.70 ± 2.01

13.00 ± 2.99

P < 0.001

HLA-G (U/mL)

80.65 ± 46.82

37.97 ± 21.47

P < 0.001

16

450

14

400

12

350
AOPP (µmol/L)

MDA (nmol/L)

Table. The mean values of the investigated parameters in the patient and the control groups
(mean ± SD).
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Figure 1. Mean MDA levels in the patient and the control groups.
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Figure 2. Mean AOPP levels in the patient and the control
groups.
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Figure 3. Mean HLA-G levels in the patient and the control
groups.
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Figure 4. Mean vitamin C levels in the patient and the control
groups.
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Figure 6. Mean R-SH levels in the patient and the control groups.

When the patient group is considered in terms of
metastasis, there were significant differences in measured
parameters between those who had lymph nodes and
those who did not (P > 0.05). Significant statistical
differences were also observed between those who had
angiolymphatic invasion and those who did not (P > 0.05).

20
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16
SOD (U/mL)

300
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Figure 5. Mean GPx levels in the patient and the control groups.
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Figure 7. Mean SOD levels in the patient and the control groups.

While there were significant positive correlations between
MDA and AOPP levels in the control group (r = 0.482, P
= 0.006), there were no significant correlations among the
other parameters measured.

4. Discussion
Epidemiologic and clinical studies show that free oxygen
radicals play an important role in cancer pathogenesis. The
damage done to the breast epithelium may cause fibroblast
proliferation, epithelial hyperplasia, cell differentiation,
and breast cancer (31–33). A number of findings from
lipid peroxidation studies indicate that in several types
of cancers, lipid peroxidation increases in solid tumors
(34,35). Although there are many studies suggesting that
the levels of MDA are high in patients with breast cancer
(36,37), there are also studies where lower levels of MDA
have been detected (38,39). Additionally, in our studies,
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in accordance with the studies where high levels of MDA
in plasma or cancerous tissues have been measured,
significantly high levels of MDA have been observed.
Reactive oxygen types and oxidative stress products
have been known to cause protein oxidation products in
protein structures as well as membrane lipids through
covalent modifications (40). Badid et al. (41) detected
significantly high levels of protein carbonyl products in
their studies with breast cancer patients. In our study, it
was also observed that in accordance with the literature,
there are significantly high proportions of AOPP in
patients with breast cancer. When the correlation of the
parameters measured in patient and control groups was
examined, a statistically remarkable correlation in the
parameters measured in the patient group was observed.
While there is a significant positive correlation between
the MDA and AOPP levels in the control group, there is
no significant correlation among the other parameters
measured.
Some studies show that oxidative stress causes
upregulation in antioxidant enzymes and that antioxidant
enzyme expression increases in cancers (41,42). The
clinical studies supporting this certify that SOD enzyme
activity in breast cancer patients is higher in accordance
with the phase of the disease (32,38). On the other hand,
in the research carried out by Gibanananda et al. (43), it
was reported that SOD and GPx activities increased, while
catalase (CAT) activity decreased.
Sinha et al. (44), however, found that the SOD and CAT
activities were significantly low in breast cancer patients
aged 30–50 whose lipid peroxidation levels in plasma
and tissues were high. Similarly, Kasapovic et al. (45)
detected that depending on age, lipid peroxidation was
high in breast cancer patients of different ages, whereas
the level of antioxidants was low. Researchers attributed
the low SOD activity observed in cancer patients to the
decrease in enzyme synthesis due to aging. In previous
studies, researchers mostly pointed out the increase in the
antioxidant enzyme activities. However, also in this study,
the findings related to the antioxidant levels support the
recent studies showing that these enzyme activities are
low. Furthermore, a difference has been observed in SOD
activities in breast cancer patients with different phases.
However, this enzyme activity was significantly low when
compared to that of healthy control groups. This difference
can be explained by the decrease in enzyme synthesis
capacity depending on age; the healthy control group was
aged 35–40, while the patient group was aged 45–65.
GSH is an important peptide inside the cell. It takes
part in many functions, ranging from antioxidant
protection to regulating cell proliferation. GPx, glutathione
S-transferase, free radicals, and peroxides play a central role
in the defense mechanisms against many xenobiotics and
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carcinogens (46). The serum levels of R-SH were examined
in this study. When compared to the control group, an
insignificant increase in R-SH was detected in patients
with breast cancer. When considered in connection with
SOD, this finding has led us to the idea that R-SH is not
a primary antioxidant in breast cancer patients. Another
important function of glutathione in an organism is
to reconvert vitamin C radicals into vitamin C formed
during the regeneration of tocopheroxyl radicals (47). In
some studies, it has been shown that there is a considerable
increase in GPx activity, which is the first phase of the
enzyme defense against H2O2 and other hydroperoxides in
tumors (41,43). High antioxidant enzyme levels and low
GSH levels were detected in breast cancer patients by Yeh
et al. (47). Although no significant differences have been
observed in total thiol levels and GPx enzyme activities,
significantly low levels of vitamin C have been measured
in breast cancer patients compared to the control group.
Ascorbic acid, together with glutathione, is known to
be the most important antioxidant in liquid phase (48).
Tocopheroxyl contributes to preventing carcinogenesis by
stimulating the immune system (49). In one study carried
out consisting of patients with breast, gastrointestinal
system, and lung cancer, Torun et al. (50) showed that lipid
peroxidation increased while vitamin C levels remained
significantly low.
In the studies conducted by Gibanananda et al. (43)
in 54 breast cancer patients in different phases, it was
shown that vitamin C levels in the patients, and especially
in phase 1 and phase 4, are significantly low compared to
those in the healthy control group. Prospective studies
come up with different results regarding the relationship
between vitamin C and breast cancer (51). In a similar
study carried out by Nissen et al. (52) it was demonstrated
that the incidence of cancer increases with the intake of
vitamin C.
It has been shown in vitro that vitamin C acts both as
an antioxidant and a prooxidant. However, in vivo studies
showed that vitamin C has mostly antioxidant effects
(52). It has been shown that HLA-G molecules, which are
associated with many diseases, play a role in pregnancy
and organ transplantations. The HLA-G expression in
trophoblasts plays a role in protecting the fetus against
the mother’s NK cells during pregnancy. In this period,
it is known that microframe and secreted cytokines and
chemokines also have a role (20–22). Findings showed
that the effect of the microenvironment has a crucial role
in HLA-G expression. Findings also support that there is
a negative feedback balance between the immune system
and HLA-G. As long as the immune system responses are
maintained within the expected balance, it is likely that
HLA-G expressions will not increase.
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Recently, a number of studies investigating the
relationship between HLA-G and malign diseases
have been published. In the study done by Palmisano
et al. (23) it was found that HLA class I molecules
totally disappeared in the low-phase tumor tissue (G1,
G2) with minimal stromal contamination. It was also
reported that no HLA-G expressions were detected.
In another study, extremely high HLA-G expressions
were found in breast cancer tissue where there was
a significant inflammation caused by immune cell
activity. HLA-G expressions have been attributed to this
inflammation (53). However, RT-PCR analysis shows
that there is an HLA-G activation at a transcriptional
phase in breast tumors (23). However, there has been no
HLA-G expression in breast cancer cell series kept in a
prolonged period of culture environment.
In the results of this study, there was a significant
statistical difference between the HLA-G levels of
the patient group and the healthy group. Statistically
significant positive correlations between HLA-G and
MDA and AOPPs were observed in this study. The high
level of plasma HLA-G has made us think that the immune
response to the tumor remained insufficient and that
the response was suppressed by HLA-G through certain
mechanisms. HLA-G expression varies depending on the
factors that are caused by microframe, tumor, or tumor
cells (54).
The cytokines and interferon secreted by the immune
cells located around the tumor have an accelerating effect
on the HLA-G expressions, especially from IL-10 tumor
cells, epithelial cells, monocytes, and macrophages (55).
IL-10, as is known, is a kind of cytokine ensuring Th2type polarization. The effect of both are considered

to be responsible for increasing immune-suppressing
pathophysiology in the development of cancer (54).
Tumor cells can express or secrete HLA-G molecules on
the surface of the cell. In the studies carried out, it has
been shown that HLA-G molecules can pass to an NK
cell activated with a cell membrane from a tumor cell that
expresses HLA-G.
In our study, when the patient group are considered
regarding metastasis, there was a significant difference
in the parameters in patients with lymph metastasis
and those without metastasis. When patients who have
angiolymphatic invasion and those who do not are
considered, no significant statistical difference has been
observed (56–58).
In light of these findings, it has been concluded that
the high levels of HLA-G in the examined breast cancer
patients at phases 2 and 3 might have caused the immune
system to be suppressed, and thus the immune system
response to the tumor remained insufficient. As it is also
shown in our findings, among the factors that change
the HLA-G expression in breast cancer, the increase in
the reactive oxygen species and an insufficient amount
of antioxidants might be effective. However, in HLA-G
expression, there is a need for further research into factors
that appear according to the stage of the cancer within a
microframe, as well as factors that are caused by the cells
themselves.
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